Founders

MICHAEL.jpg

Christopher Pettigrew

Christopher obtained his Honours B.Sc. in Cellular & Molecular Biology and Economics from the University of Toronto.  He has extensive research experience with the yeast Saccharomyces cerevisiae.  He is particularly familiar with cellular lifespan assays and the utility of various yeast models of human cellular aging.
 

 

 

 

Michael Pettigrew

Michael graduated from the University of Toronto with a B.A.Sc. in Engineering Science, majoring in biomedical engineering, and a Certificate in Engineering Business. His primary expertise is in the area of cellular bioengineering. He has worked in a number of leading laboratories on a diverse range of projects in the fields of synthetic biology, computational neuroscience, and biophotonics.


Advisors

Corey.jpg

Dr. Corey Nislow

Dr. Nislow is an Associate Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia. He completed his Ph.D. in Cell and Molecular Biology at the University of Colorado and was an American Cancer Society Postdoctoral Fellow. He previously served as group leader in two biotechnology companies, as a Senior Genome Scientist at Stanford University, and as an Associate Professor at the University of Toronto and Director of the Donnelly Sequencing Centre. His lab develops biotechnology tools including parallel genome-wide chemical genomic screens, high throughput cell-based screens and next generation sequencing to address fundamental and applied biological questions.

Rob Klein

Rob is an executive who has been instrumental in crafting, analyzing, and executing strategic operational plans that have enabled organizations to obtain their objectives. A few examples of his accomplishments include helping companies raise $250+ million in debt and equity financing, partnering with Wind Mobile in the successful execution of their $442 million bid in the 2008 AWS auction, leading a cross-functional team that successfully launched Bell Canada’s National Hosting Services, partnering with Swiss Medica to enable them to grow their 3-year revenue from $100,000 to $6.4 million, and partnering with FutureLink to grow to a US$2.0+ billion market cap.